Search results for "EWS"

showing 10 items of 1197 documents

Skin conductance measurement for the assessment of analgosedation adequacy in infants treated with mechanical ventilation: A multicenter pilot study

2020

Background Patients treated in neonatal/pediatric intensive care units (N/PICUs) are frequently exposed to pain. To assess its severity, several behavioral and behavioral-physiological scales are used, but their usefulness is limited. It is therefore justified to search for additional methods to assess the adequacy of analgesia and sedation in these patients. Objectives To evaluate the usefulness of skin conductance (SC) measurement in the assessment of analgosedation quality in infants requiring mechanical ventilation treated in N/PICUs. Material and methods Thirty infants aged 6-208 days treated in 6 N/PICUs, mechanically ventilated and receiving analgosedation, were included for the stud…

COMFORT-B scaleSedationmedicine.medical_treatmentMedicine (miscellaneous)Pilot ProjectsIntensive Care Units PediatricGeneral Biochemistry Genetics and Molecular Biologyskin conductanceIntensive careInternal MedicinemedicineHumansPharmacology (medical)painChildGenetics (clinical)Mechanical ventilationAlgesimeterbusiness.industryInfant NewbornRespiration ArtificialinfantClinical PracticeAnesthesiaReviews and References (medical)analgosedationmedicine.symptomAnalgesiabusinessSkin conductanceAdvances in Clinical and Experimental Medicine
researchProduct

In the literature: February 2019

2019

Malignant pleural mesothelioma (MPM) is a rare and lethal cancer associated to asbestos exposure. Currently, the pemetrexed and cisplatin combination chemotherapy remains the only approved treatment. In the last 5 years, a growing knowledge on mesothelioma pathobiology has translated into the development of multiple novel therapeutic strategies.1 One of the largest reports of comprehensive genomic profiling of MPM was conducted by Bueno and colleagues. Using RNA-seq data, they identified four distinct molecular subtypes, and through exome analysis, they found that BAP1 , NF2 , TP53 , SETD2 , DDX3X , ULK2 , RYR2 , CFAP45 , SETDB1 and DDX51 were significantly mutated.2 In an article recently …

Cancer ResearchBAP1business.industryCombination chemotherapyNewslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaselcsh:RC254-282PemetrexedMRNA SequencingOncologySETD2DNA methylationCancer researchmedicine1506MesotheliomabusinessExomemedicine.drugESMO Open
researchProduct

In the literature: June 2018

2018

Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are a highly active family of compounds that have changed the scenario in ovarian and human epidermal growth factor receptor 2 (HER2) non-amplified breast cancer management in the recent years. Despite impressive clinical activity, a prolonged treatment with PARPi is frequently associated with acquired resistance to this therapy. The identification of mechanisms and strategies to overcome resistance are crucial. Bromodomain containing 4 (BRD4) is a member of the bromodomain and extraterminal (BET) protein family that facilitates oncogenic transcription. BRD4 is frequently amplified in high-grade serous ovarian cancer (HGSOC) and can be …

Cancer ResearchBRD4ARID1AliteratureRAD51BiologyNewsBromodomainOncologyCancer cellCancer researchbiology.proteinPTENEctopic expression1506PI3K/AKT/mTOR pathwayESMO Open
researchProduct

In the literature: June 2020.

2020

Immunotherapy based on checkpoint blockade has revolutionised cancer treatment during last years. Whereas this approach fails in a relevant group of patients, the knowledge on tumour microenvironment (TME) opened the possibility to the use of additional therapeutic strategies to potentiate antitumour immunity, including depletion of protumourigenic or immune suppressive and activation of specific immune populations using agonistic antibodies. Nevertheless, due to the complexity of the TME, many of these strategies have been indiscriminately advanced to the clinic without clear mechanistic hypotheses. Nowadays, single-cell RNA sequencing (scRNA-seq)-based transcriptome analyses identify T ce…

Cancer ResearchCD40AngiogenesisT cellmedicine.medical_treatmentAntigen presentationImmunotherapyBiologyNewslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282not applicableImmune systemmedicine.anatomical_structureOncologyCancer cellbiology.proteinmedicineCancer research1506AntibodyESMO open
researchProduct

In the literature: December 2019

2020

The introduction of new high-throughput technologies in oncology and the need to apply precision medicine for cancer patients has led to the detection of several molecular alterations. Among them, activating mutations of ERBB2 have been reported in many solid tumours. In the last years, several clinical trials with covalent tyrosine kinase inhibitors (TKIs) for ERBB2 mutant cancers have been conducted, with different results among several cancer types. In the SUMMIT trial, neratinib was most effective in breast cancer patients, with the majority of responders having tumours with L755S, V777L, or L869R ERBB2 mutations.1 In an elegant article published in C ancer C ell by Robichaux et al ,2 d…

Cancer ResearchMutationbusiness.industryAfatinibCancerPoziotinibNewsmedicine.disease_causemedicine.diseaseDacomitinibchemistry.chemical_compoundExonBreast cancerOncologychemistryNeratinibmedicineCancer research1506businessmedicine.drugESMO Open
researchProduct

In the literature: February 2021

2021

Cancer ResearchText miningOncologybusiness.industryLibrary scienceMedicineNewsbusinessESMO Open
researchProduct

In the literature: December 2020

2021

Cancer ResearchText miningOncologybusiness.industryLibrary scienceMedicineNewsbusinessESMO Open
researchProduct

In the literature: October 2021

2021

Cancer ResearchText miningOncologybusiness.industryLibrary scienceMedicineNewsbusinessESMO Open
researchProduct

In the literature: June 2021

2021

Cancer ResearchText miningOncologybusiness.industryMEDLINELibrary scienceMedicineNewsbusinessESMO Open
researchProduct

In the literature: April 2021

2021

Cancer ResearchText miningOncologybusiness.industryMedicineLibrary scienceNewsbusinessESMO Open
researchProduct